文献速递骨显像与常规 SPECT放射性药物与辐射防护

99mTc-MDP全身骨显像中报告放射性药物外渗后注射部位不良临床事件极为罕见:12年经验

Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing 99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year Experience.
PubMed 文献 · J Nucl Med · 2022-10-20

该回顾性研究分析了2010年6月至2022年1月31,679例99mTc-MDP全身骨显像,其中118例(0.37%)报告放射性药物外渗,最终纳入96例患者。中位随访18.9个月,4例出现短期事件,其中3例有症状(2例轻度不适,1例触痛性肿胀),且3例均有当日先行CT增强对比剂外渗史;无长期不良事件与外渗有合理关联。

要点

  • 99mTc-MDP全身骨显像中报告的外渗率为0.37%(118/31,679)。
  • 96例外渗患者中仅3例(0.009%)出现短期局部症状,均可能与先前高容量CT对比剂外渗有关。
  • 无患者发生与外渗有合理关联的长期不良事件。

核心结论

  • 报告的外渗罕见,3例(0.009%)出现短期局部症状,均可能与先前较高容量静脉对比剂外渗有关。
  • 用于全身骨显像的较小容量诊断性放射性药物注射本身极不可能引起局部症状。
  • 无患者发生与外渗有合理关联的长期不良事件。

研究设计与样本

  • 回顾性分析2010年6月至2022年1月期间进行的99mTc-MDP全身骨显像记录,筛查扫描报告中记录的外渗。
  • 共审查31,679例99mTc-MDP全身骨显像,118例(0.37%)记录外渗,22例病历无法获取,最终队列为96例患者。
  • 中位随访18.9个月(四分位距7.8-45.7个月),审查短期(2周内)和长期不良事件。

主要发现

  • 31,679例99mTc-MDP全身骨显像中,118例(0.37%)报告放射性药物外渗。
  • 96例最终队列中,4例发生短期事件,其中1例无症状;3例有症状者中2例注射部位轻度不适,1例触痛性肿胀。
  • 4例短期事件中3例患者当日较早时曾因对比增强CT发生静脉对比剂外渗,随后在同一部位注射99mTc-MDP,可能导致了放射性药物外渗。
  • 无长期局部事件与放射性药物外渗有合理关联。

局限性

  • 原文为回顾性研究。
  • 22例患者病历无法获取。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The deleterious effects of high-dose radiation on normal tissue are sometimes extrapolated to diagnostic (SPECT and PET) radiopharmaceutical extravasation (RPE). It has been hypothesized that diagnostic RPE can have gradually evolving local tissue injury and a potentially increased risk of local dermatologic or oncologic diseases over a longer period. However, data on clinical adverse events after diagnostic RPE are limited. Therefore, our primary aim was to study the occurrence of short-term and long-term clinical adverse events in patients who underwent 99mTc-methylene diphosphonate (99mTc-MDP) whole-body bone scintigraphy (WBBS) with reported RPE. Methods: The records of 99mTc-MDP WBBS performed from June 2010 to January 2022 were retrospectively examined for RPE documented in the scan reports. The clinical records of patients with a documented RPE were extensively reviewed for any related short-term adverse events (within 2 wk of the WBBS: local symptoms and care sought for local dermatologic or musculoskeletal issues) and long-term adverse events (until the last follow-up: local deleterious effects and related consults for dermatology, plastic surgery, oncology, or orthopedics). Results: Retrospective review of the records of 31,679 99mTc-MDP WBBS studies showed RPE documented in 118 (0.37%). Medical records were not retrievable for 22 patients, yielding a final cohort of 96 patients with reported RPE. The median follow-up was 18.9 mo (interquartile range, 7.8-45.7 mo). Short-term events were noted in 4 patients, of whom one was asymptomatic. Of the 3 symptomatic patients, 2 experienced mild discomfort at the injection site, and 1 had tender swelling. Three of the 4 events were in patients who had a prior intravenous contrast extravasation for contrast-enhanced CT performed earlier during the day and a 99mTc-MDP injection later at the same site, likely leading to RPE. None of the long-term local events had any plausible link with the RPE event. Conclusion: Reported RPE was rare, and 3 patients (0.009%) had short-term local symptoms, all of which were likely related to the prior higher-volume intravenous contrast extravasation. The smaller-volume diagnostic radiopharmaceutical injections for WBBS are highly unlikely to cause local symptoms on their own. No patient had any long-term adverse event with a plausible link to the RPE.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Parihar AS, Schmidt LR, Crandall J, et al. Adverse Clinical Events at the Injection Site Are Exceedingly Rare After Reported Radiopharmaceutical Extravasation in Patients Undergoing 99mTc-MDP Whole-Body Bone Scintigraphy: A 12-Year Experience. J Nucl Med. 2022. PMID: 36265907. doi:10.2967/jnumed.122.264994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。